Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC4EDIT Japan asciminib observational study in early-line chronic phase CML
jRCT1071250081Recruiting
- Sponsor
- Novartis
- Start
- Oct 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of asciminib in chronic myelogenous leukemia (CML), sponsored by Novartis. Primary endpoint: MR4.5 achievement rate at 48 weeks. Started Oct 2025; status: recruiting.
02
Drugs
asciminib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on jRCT1071250081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1071250081.